Current Role of Magnetic Resonance Imaging in Breast Imaging: A Primer for the Primary Care Physician

References

1. ↵
   Rankin SC. MRI of the breast. Br J Radiol 2000; 73: 806–18.

   OpenUrlAbstract
2. ↵
   Majid AS, de Paredes ES, Doherty RD, et al. Missed breast carcinoma: pitfalls and pearls. Radiographics. 2003; 23: 881–95.

   OpenUrlPubMedWeb of Science
3. ↵
   Doi K, MacMahon H, Katsuragawa S, et al. Computer-aided diagnosis in radiology: potential and pitfalls. Eur J Radiol 1997; 31: 97–109.
4. ↵
   Plevritis SK, Ikeda DM. Ethical issues in contrast-enhanced magnetic resonance imaging screening for breast cancer. Top Magn Reson Imaging 2002; 13: 79–84.

   OpenUrlPubMed
5. ↵
   Heywang-Kobrunner SH, Viehweg P, Heinig A, Kuchler C. Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions. Eur J Radiol 1997; 24: 94–108.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   Bluemke DA, Gatsonis CA, Chen MH, et al. Magnetic resonance imaging of the breast prior to biopsy. JAMA 2004; 292: 2375–742.

   OpenUrl
7. ↵
   Brant WE. Diagnostic imaging methods. In: Brant WE, Helms CA, editors. Fundamentals of Diagnostic Radiology, 2nd ed. Philadelphia (PA): Lippincott Williams and Wilkins; 1999. p. 19.
8. Ose K, Doue T, Zen K, et al. Gadolinium as an alternative to iodinated contrast media for x-ray angiography in patients with severe allergy. Circ J 2005; 69: 507–9.

   OpenUrlPubMed
9. Sam AD II, Morasch MD, Collins J, et al. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 2003; 38: 313–8.

   OpenUrlCrossRefPubMedWeb of Science
10. Thomsen HS. Gadolinium-based contrast media may be nephrotoxic even at approved doses. Eur Radiol 2004; 14: 1654–6.

    OpenUrlPubMedWeb of Science
11. ↵
    Morris EA. Breast cancer imaging with MRI. Radiol Clin North Am 2002; 40: 443–66.

    OpenUrl
12. ↵
    Iglehart DJ, Kaelin CM. Diseases of the breast. In: Townsend CM, Beauchamp RD, Evers BM, Mattox KL, editors. Sabiston Textbook of Surgery 17th ed. Philadelphia (PA): Elsevier; 2004. p. 867.
13. ↵
    Feig SA, Orel SG, Dershaw DD. The breast. In: Grainger RG, Allison D, Adam A, Dixon AK, editors. Grainger & Allison’s Diagnostic Radiology: A Textbook of Medical Imaging, 4th ed. Orlando (FL): Churchill Livingstone; 2001. p. 2268–72.
14. ↵
    Kinkel K, Hylton N. Challenges to interpretation of breast MRI. J Magn Reson Imaging 2001; 13: 821–9.

    OpenUrlCrossRefPubMed
15. ↵
    Schnall MD, Ikeda DM. Lesion diagnosis working group report. J Magn Reson Imaging 1999; 10: 982–90.

    OpenUrlCrossRefPubMed
16. ↵
    Kinkel K, Vlastos G. MR imaging: breast cancer staging and screening. Semin Surg Oncol 2001; 20: 187–96.

    OpenUrlCrossRefPubMed
17. ↵
    Schelfout K, Van Goethem M, Kersschot E, et al. Contrast-enhanced MR imaging of breast lesions and effect on treatment. Eur J Surg Oncol 2004; 30: 501–7.

    OpenUrlCrossRefPubMed
18. Bedrosian I, Mick R, Orel SG, et al. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer 2003; 98: 468–73.

    OpenUrlCrossRefPubMedWeb of Science
19. Riber A, Schirrmeister H, Gabelmann A, et al. Pre-operative staging of invasive breast cancer with MR mammography and/or PET: boon or bunk?. Br J Radiol 2002; 75: 789–98.

    OpenUrlAbstract/FREE Full Text
20. Fischer U, Kopka L, Grabbe E. Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. Radiology 1999; 213: 881–8.

    OpenUrlPubMedWeb of Science
21. Esserman L, Hylton N, Yassa L, et al. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol 1999; 17: 110–9.

    OpenUrlAbstract/FREE Full Text
22. Rodenko GN, Harms SE, Pruneda JM, et al. MR imaging in the management before surgery of lobular carcinoma of the breast: correlation with pathology. AJR 1996; 167: 1415–9.

    OpenUrlPubMedWeb of Science
23. Boetes C, Veltman J, van Die L, et al. The role of MRI in invasive lobular carcinoma. Breast Cancer Res Treat 2004; 86: 31–7.

    OpenUrlCrossRefPubMedWeb of Science
24. Van Goethem M, Schelfout K, Dijckmans L, et al. MR mammography in the preoperative staging of breast cancer in patients with dense breast tissue: comparison with mammography and ultrasound. Eur Radiol 2004; 14: 809–16.

    OpenUrlCrossRefPubMed
25. ↵
    Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR 2005; 184: 868–77.

    OpenUrlCrossRefPubMedWeb of Science
26. Chen X, Moore MO, Lehman CD, et al. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. Acad Radiol 2004; 11: 1115–24.

    OpenUrlCrossRefPubMedWeb of Science
27. Denis F, Desbiez-Bourcier AV, Chapiron C, et al. Contrast enhanced magnetic resonance image underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. Eur J Surg Oncol 2004; 30: 1069–76.

    OpenUrlCrossRefPubMed
28. Tozaki M, Uno S, Kobayashi T. Histologic breast cancer extent after neoadjuvant chemotherapy: comparison with multidetector-row CT and dynamic MRI. Radiat Med 2004; 22: 246–53.

    OpenUrlPubMed
29. Bodini M, Berruti A, Bottini A, et al. Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy [abstract]. Breast Cancer Res Treat 2004; 85: 211–8.

    OpenUrlCrossRefPubMedWeb of Science
30. Warren RM, Bobrow LG, Earl HM, et al. Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy? Br J Cancer 2004; 90: 1349–60.

    OpenUrlCrossRefPubMedWeb of Science
31. Lee JM, Orel SG, Czerniecki BJ, et al. MRI before reexcision surgery in patients with breast cancer. AJR 2004; 182: 473–80.

    OpenUrlPubMed
32. Rosen EL, Blackwell KL, Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR 2003; 181: 1275–82.

    OpenUrlCrossRefPubMedWeb of Science
33. Hwang ES, Kinkel K, Esserman LJ, et al. Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. Ann Surg Oncol 2003; 10: 381–8.

    OpenUrlCrossRefPubMedWeb of Science
34. Belli P, Romani M, Costantini M, et al. Role of magnetic resonance imaging in the pre and postchemotherapy evaluation in locally advanced breast carcinoma [abstract]. Rays 2002; 27: 279–90.

    OpenUrlPubMed
35. Cheung YC, Chen SC, Su MY, et al. Monitoring the size and response of locally advanced breast cancer to neoadjuvant chemotherapy (weekly paclitaxel and epifubicin) with serial enhanced MRI. Breast Cancer Res Treat 2003; 78: 51–8.

    OpenUrlCrossRefPubMedWeb of Science
36. Partridge SC, Gibbs JE, Lu Y, et al. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR 2002; 179: 1193–9.

    OpenUrlCrossRefPubMedWeb of Science
37. Kawashima H, Tawara M, Suzuki M, et al. Effectiveness of dynamic MRI for diagnosing pericicatricial minimal residual breast cancer following excisional biopsy. Eur J Radiol 2001; 40: 2–9.

    OpenUrlPubMed
38. Drew PJ, Kerin MJ, Mahapatra T, et al. Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast. Eur J Surg Oncol 2001; 27: 617–20.

    OpenUrlCrossRefPubMed
39. Weatherall PT, Evans GF, Metzger GJ. MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with x-ray mammography and palpation. J Magn Reson Imaging 2001; 13: 868–75.

    OpenUrlCrossRefPubMed
40. Frei KA, Kinkel K, Boenl HM, et al. MR imaging of the breast in patients with positive margins after lumpectomy: influence of the time interval between lumpectomy and MR imaging. AJR 2000; 175: 1577–84.

    OpenUrlPubMed
41. Trecate G, Ceglia E, Stabile F, et al. Locally advanced breast cancer treated with primary chemotherapy: comparison between magnetic resonance imaging and pathological evaluation of residual disease [abstract]. Tumori 1999; 85: 220–8.

    OpenUrlPubMedWeb of Science
42. Orel Sg, Reynolds C, Schnall MD, et al. Breast carcinoma: MR imaging before re-excisional biopsy. Radiology 1997; 205: 429–36.

    OpenUrlPubMed
43. Soderstrom CE, Harms SE, Farrell RS, et al. Detection with MR imaging of residual tumor in the breast soon after surgery. AJR 1997; 168: 485–8.

    OpenUrlPubMed
44. ↵
    Fischer U, Zachariae O, Baum F, et al. The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer [abstract]. Eur Radiol 2004; 14: 1725–31.

    OpenUrlPubMedWeb of Science
45. ↵
    Olson JA, Jr., Morris EA, Van Zee KJ, et al. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol 2000; 7: 411–5.

    OpenUrlCrossRefPubMed
46. Henry-Tillman RS, Harms SE, Westbrook KC, et al. Role of breast magnetic resonance imaging in determining breast as a source of unknown metastatic lymphadenopathy. Am J Surg 1999; 178: 496–500.

    OpenUrlCrossRefPubMed
47. Orel SG, Weinstein SP, Schnall MD, et al. Breast MR imaging in patients with axillary node metastases and unknown primary malignancy. Radiology 1999; 212: 543–9.

    OpenUrlPubMedWeb of Science
48. ↵
    Lindfors KK. Breast imaging. In: Brant WE, Helms CA, editors. Fundamentals of Diagnostic Radiology, 2nd ed. Philadelphia (PA): Lippincott Williams and Wilkins; 1999. p. 493, 512–3.
49. ↵
    Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292: 1317–25.

    OpenUrlCrossRefPubMedWeb of Science
50. ↵
    Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351: 427–37.

    OpenUrlCrossRefPubMedWeb of Science
51. ↵
    Imaginis. Magnetic resonance breast imaging (MRI, MR). May 2005. Available at: http://imaginis.com/breasthealth/mri.asp. Accessed on: June 3, 2005.
52. Breast Cancer Action. Newsletter #39-December 1996/January 1997. Available at: http://www.bcaction.org/Pages/SearchablePages/1996Newsletters/Newsletter039G.html. Accessed on: June 3, 2005.
53. Mettler FA. Essentials of Radiology, 2nd ed. Philadelphia (PA): Elsevier; 2005. p. 401.
54. ↵
    Morris EA, Liberman L, Ballon DJ, et al. MRI of occult breast carcinoma in a high risk population. AJR 2003; 181: 619–26.

    OpenUrlPubMedWeb of Science
55. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365: 1679–78.

    OpenUrl
56. Lehman CD, Blume JD, Weatherall P, et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer. 2005; 103: 1898–905.

    OpenUrlCrossRefPubMedWeb of Science
57. Podo F, Sardanelli F, Canese R, et al. The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk [abstract]. J Exp Clin Cancer Res 2002; 21(3 Suppl): 115–24.

    OpenUrl
58. Sim LS, Hendriks JH, Fook-Chong SM. Breast ultrasound in women with familial risk of breast cancer. Ann Acad Med Singapore. 2004; 33: 600–6.

    OpenUrlPubMed
59. ↵
    Warner E. Intensive radiologic surveillance: a focus on the psychological issues [abstract]. Ann Oncol 2004; 15 Suppl 1: 143–7.

    OpenUrl
60. ↵
    Rijnsburger AJ, Essink-Bot ML, van Dooren S, et al. Impact of screening for breast cancer in high-risk women on health-related quality of life. Br J Cancer. 2004; 91: 69–76.

    OpenUrlCrossRefPubMed